What is the appropriate management for a patient with a platelet count of 1,130 × 10⁹/L, acute‑on‑chronic anemia, and colon cancer?

Management of Thrombocytosis (Platelet Count 1,130 × 10⁹/L) in Colon Cancer with Acute-on-Chronic Anemia

This patient requires immediate investigation of the underlying cause of anemia and thrombocytosis, with priority given to treating the anemia through transfusion if symptomatic (Hb <10 g/dL) while addressing the colon cancer definitively through surgical resection or systemic therapy.

Primary Management Priorities

1. Anemia Management

The acute-on-chronic anemia in colon cancer demands immediate attention as it directly impacts morbidity and quality of life:

• If Hb <10 g/dL with symptoms: Administer RBC transfusion immediately 1
• Assess iron status: Check serum ferritin, transferrin saturation, and inflammatory markers (CRP)
  • If ferritin <30 ng/mL and CRP <5 mg/L: Consider oral iron
  • If ferritin 30-800 ng/mL or CRP elevated: Use IV iron (1000 mg single dose or equivalent) 1

Critical caveat: While iron therapy treats anemia, emerging evidence suggests it may potentially support tumor growth in colorectal cancer by amplifying Wnt signaling in APC-mutated tumors 2. However, symptomatic anemia correction takes precedence for immediate quality of life and surgical candidacy.

2. Thrombocytosis Evaluation

A platelet count of 1,130 × 10⁹/L represents marked thrombocytosis that requires differentiation:

• Reactive thrombocytosis (most likely): Secondary to chronic bleeding, iron deficiency, inflammation, or malignancy itself
• Essential thrombocythemia: Less likely but requires JAK2, CALR, MPL mutation testing if clinically suspected

The thrombocytosis itself does NOT require cytoreductive therapy in this cancer context - it will likely resolve with treatment of the underlying colon cancer and correction of iron deficiency 3.

3. Thrombosis Risk Assessment and Prophylaxis

Despite the elevated platelet count, this patient remains at high risk for venous thromboembolism (VTE) due to:

• Active malignancy (colon cancer)
• Likely iron deficiency contributing to thrombocytosis
• Potential immobilization

Anticoagulation strategy with platelet count >50 × 10⁹/L 4:

• If no active VTE: Prophylactic LMWH (enoxaparin 40 mg daily or equivalent) is appropriate
• If acute VTE develops: Full therapeutic anticoagulation without platelet transfusion support is recommended, as platelet count is well above 50 × 10⁹/L 4
• LMWH is preferred over DOACs in gastrointestinal malignancies due to lower bleeding risk 4

4. Surgical and Oncologic Considerations

Preoperative optimization:

• Target Hb ≥10 g/dL before elective surgery to minimize perioperative transfusion requirements 3
• Platelet count >100 × 10⁹/L is adequate for surgery; this patient's count of 1,130 × 10⁹/L poses no contraindication 5
• Consider holding prophylactic anticoagulation 12-24 hours before surgery

Perioperative transfusion strategy:

• Minimize allogeneic transfusions when possible, as they may increase infection risk and potentially tumor recurrence 6, 3
• Transfuse only for symptomatic anemia or Hb <7-8 g/dL perioperatively

Algorithmic Approach

Step 1: Check CBC, iron panel (ferritin, TSAT), CRP, peripheral smear

• Right colon cancer: Expect lower Hb (mean 33 g/dL) and higher likelihood of iron deficiency 3
• Left colon/rectal cancer: Typically less severe anemia

Step 2: Transfuse if Hb <10 g/dL AND symptomatic (fatigue, dyspnea, tachycardia)

Step 3: Initiate IV iron 1000 mg if ferritin 30-800 ng/mL (functional iron deficiency) 1

Step 4: Start prophylactic LMWH unless contraindicated

Step 5: Proceed with cancer staging and definitive treatment (surgery or chemotherapy)

• Thrombocytosis will resolve with cancer treatment and iron repletion
• Monitor platelets post-treatment; persistent elevation >6 months warrants hematology evaluation

Common Pitfalls to Avoid

1. Do NOT treat thrombocytosis with cytoreductive agents (hydroxyurea, anagrelide) in reactive thrombocytosis - this is unnecessary and potentially harmful
2. Do NOT withhold anticoagulation based on elevated platelet count alone; VTE risk remains high in cancer
3. Do NOT delay surgery to normalize platelet count - the current level is safe for procedures
4. Do NOT use DOACs as first-line anticoagulation in GI malignancies due to increased bleeding risk compared to LMWH 4
5. Do NOT give prophylactic platelet transfusions - they are contraindicated in reactive thrombocytosis and provide no benefit 5

The thrombocytosis in this case is a marker of the underlying pathology (chronic bleeding, iron deficiency, inflammation from cancer) rather than a primary problem requiring specific treatment. Focus remains on definitive cancer management and anemia correction.